If the deal is structured appropriately then "spinning" off the UBand would reap a large profit very quickly.
You could argue that they are leaving money on the table by not marketing the UBand themselves but, at the same time, they are avoiding the risk/hassle associated with entering a new market and competing with large established players like Dexcom and Abbott Labs.
They would also avoid the FDA approval process which is a potential minefield for small biotechs.
News 
Market Data 
Discover 
